In addition to the data reported in our systematic review and meta-analysis 'Current Evidence on Omega-3 Fatty Acids in Enteral Nutrition in the Critically ill' we present data on intensive care unit and hospital mortality, age distribution between included studies, tolerability and adverse events of enteral omega-3 supplementation compared with control interventions in the critically ill. Moreover, we report additional analyses on 28-day mortality comparing old versus new studies and high versus low quality trials. Finally, we report baseline and follow-up levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reported in the trials included in . For further interpretation and discussion we recommend reading our systematic review and meta-analysis Current Evidence on Omega-3 Fatty Acids in Enteral Nutrition in the Critically ill'.
Specifications table
Subject area Medicine More specific subject area Analysis of data on omega-3 fatty acids in critical care nutrition Type of data Tables and figures  How data was acquired Data were acquired through meta-analysis of 24 RCT's on enteral omega-3 fatty acid supplementation in critically ill patients Data format Analyzed Experimental factors
Critically ill patients receiving enteral omega-3 fatty acid supplementation included in randomized controlled trials were included Experimental features Forest plots were generated and relative risk ratio's calculated to show the effects of omega-3 fatty acid supplementation Data source location A systematic review was conducted to identify all relevant randomized clinical trials published before January 2018 in MEDLINE, Embase, CINAHL and the Cochrane Central Register of Controlled Trials. Data accessibility A systematic review was conducted to identify all relevant randomized clinical trials published before January 2018 in MEDLINE, Embase, CINAHL and the Cochrane Central Register of Controlled Trials.
Value of the data
The data on tolerability and adverse events are helpful in a risk-benefit analysis of omega-3 supplementation in the critically ill.
Data on ICU and hospital mortality provide more information on safety of omega-3 interventions. Data on age distribution between studies may be helpful in interpretation of results and may give rise to specific treatment of age-groups.
Data on EPA and DHA baseline and follow-up levels may be of value in interpretation of the effects of omega-3 supplementation as they may be related to serum levels.
Data
We share data regarding ICU and hospital mortality, age distribution between included studies in [1] , tolerability and adverse events of enteral omega-3 supplementation compared with placebo in the critically ill. Fig. 1 shows the effects of fish oil supplementation on ICU mortality in different ICU populations. Fig. 2 shows the effects of fish oil supplementation on hospital mortality in different ICU populations. In Fig. 3 the effects of fish oil supplementation on 28-day mortality, comparing old versus new randomized controlled trials (RCTs) are reported. In Fig. 4 the effects of fish oil supplementation on 28-day mortality, comparing high versus low quality RCTs are shown. Adverse events registered in the trials included in [1] are reported in Fig. 5 . Table 1 reports baseline and follow-up EPA and DHA levels. Furthermore, Table 2 reports on age distribution in the studies included in [1] . Additionally, tolerability of omega-3 supplementation in ICU patients is reported in Table 3 .
Experimental design, materials and methods
The search strategy, study identification and selection criteria used to acquire the data presented in this article are reported in [1] . Age is reported in mean 7 standard deviation unless otherwise specified. * median with range^median with interquartile range # mean 7 standard error of the mean. 
